ERAS: the cash flow

MyFinsight

For the year ending 2025-12-31, ERAS had $6,066K increase in cash & cash equivalents over the period. -$95,583K in free cash flow.

Cash Flow	2025-12-31
Net loss	-124,546
Depreciation and amortization	3,107
Stock-based compensation expense	24,899
In-process research and development expenses	9,500
Accretion on marketable securities, net	5,087
Prepaid expenses and other current and long-term assets	-1,789
Accounts payable	513
Accrued expenses and other current and long-term liabilities	-3,768
Operating lease assets and liabilities, net	1,862
Net cash used in operating activities	-95,455
Purchases of marketable securities	150,974
Maturities of marketable securities	261,027
In-process research and development	9,500
Purchases of property and equipment	128
Net cash provided by (used in) investing activities	100,425
Proceeds from the exercise of stock options	372
Proceeds from issuance of common stock under the employee stock purchase plan	724
Net cash provided by financing activities	1,096
Net increase (decrease) in cash, cash equivalents, and restricted cash	6,066
Cash, cash equivalents and restricted cash at beginning of the period	68,147
Cash, cash equivalents and restricted cash at end of the period	74,213

Unit: Thousand (K) dollars (except for numbers of shares and EPS).